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Abstract
Kim’s overview of Food and Drug Administration (FDA) regulatory actions from 2005 to 2014 is a 
comprehensive analysis of the US regulatory experience with online direct-to-consumer advertising 
(DTCA) of prescription medicines. This experience is of relevance internationally as online DTCA reaches 
the English-speaking public globally, despite the illegality of DTCA in most countries. The most common 
violations were omissions or minimizations of risk information, overstatements of efficacy, unsubstantiated 
claims, and promotion of unapproved (“off-label”) use. Nearly one fourth of violations involved cancer 
drugs, raising additional concerns about patient vulnerability, limited treatment advance, and high costs. 
Based on content analyses of online DTCA, these cases likely reflect a small proportion of unbalanced and 
misleading promotional information available on the web. The FDA is only able to review a small proportion 
of promotional materials submitted to them, due to limited staffing, and the delay between first posting and 
regulatory action means that many people may be exposed to messages that are found to be inaccurate and 
misleading. The sheer volume of online DTCA, combined with the ability for content to shift continually, 
poses unique regulatory challenges. 
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Introduction
Most industrialized countries, with the exception of the 
United States and New Zealand, prohibit direct-to-consumer 
advertising (DTCA) of prescription-only medicines as a health 
protection measure. DTCA has the potential to harm the 
public in two main ways. If  advertising convinces people to 
take a medicine they do not need and that is unlikely to benefit 
them, the potential for harm is likely to outweigh benefit. If it 
convinces them to choose a medicine that is less safe or less 
effective than available alternatives, users’ health is also likely 
to suffer. DTCA played a prominent role for example in the 
promotion of the arthritis drug rofecoxib (Vioxx), withdrawn 
globally in 2005 due to an increased risk of heart attack.1,2 A 
range of equally effective, less costly and less toxic alternatives 
were available. The advertisements, featuring ex-Olympic 
skater Dorothy Hamill gliding effortlessly on the ice, gave the 
impression of otherwise unattainable active, pain-free living. 
The other main potential for harm is to healthcare costs, if 
advertising convinces people to use expensive products 
that are no better than alternatives. Cost and affordability 
concerns led the American Medical Association (AMA) to 
call for a ban on DTCA in November 2015.3 
The Regulatory Experience With Online Direct-to-Consumer 
Advertising
Regulatory oversight aims to protect the public, in part 
through enforced information standards to prevent exposure 
to inaccurate and misleading information. In her paper, 
“trouble spots in online direct-to-consumer prescription drug 
promotion: a content analysis of FDA warning letters,” Hyosun 
Kim analyzed US Food and Drug Administration (FDA) 
regulatory actions concerning online DTCA over a 10-year 
period, from 2005 and 2014.4  This is a comprehensive analysis 
of the US regulatory experience with online DTCA, which 
provides important insights into the types of information and 
activities the FDA has judged to be in violation of US law. One 
previous study examined FDA letters of violation on online 
promotion to 20125; results complement Kim’s analysis, 
also documenting a pattern of violations in which safety 
information is often omitted. US regulation of online DTCA 
is relevant internationally, as this advertising reaches much of 
the English-speaking world. Manufacturers’ brand-specific 
websites, for example, are accessible in many countries, 
regardless of the location of the computer’s IP address. Some 
websites are labeled as being ‘for US residents only’ but this 
labeling is not always present or prominent, and rarely blocks 
access. In 2010, the 10 largest drug companies globally had 
corporate Facebook pages, Twitter feeds and sponsored blogs 
or RSS feeds; 8/10 top products, by global sales, had DTCA 
ads on YouTube and 9/10 had a dedicated Facebook page.6
Kim identified 73 letters listing 179 violations.4 The most 
common were omissions or minimizations of information on 
risks, followed by overstatements of efficacy, unsubstantiated 
claims, and misrepresentation of the indication for use. The 
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most common treatment area was cancer; nearly one fourth 
of the letters were about advertisements of cancer treatments. 
This raises additional concerns because of extra vulnerability 
of cancer patients when faced with a life-threatening disease. 
An example is the 2010 FDA warning letter on advertising 
of nilotinib (Tasigna), a leukemia treatment, on ‘Facebook 
Share,’ in which information on the risk of sudden death was 
omitted, the posting failed to state this drug was approved 
only for those who had failed on previous treatment, and the 
text implied superior efficacy, despite the lack of evidence 
to support this claim.7 Another concern specific to cancer 
treatments is the very high cost of many new cancer drugs 
and limited evidence of advantage over existing drugs, with 
average survival improvements of only one to two months.8
Banner ads in Internet search engines were featured in one 
fourth of FDA letters over this 10-year period. In April 2009, 
the FDA sent regulatory letters to 14 companies because of 
omission of risk information in banner ads. This included 
for example the banner for Avandia (rosiglitazone), which 
included the brand name, the statement that this was the 
“Avandia official site” and the tag line “See How Avandia 
Can Help Patients Living with Type 2 Diabetes.”9 April 2009 
was 18 months after the FDA had required a boxed warning 
of increased heart attack risks in rosiglitazone’s labeling.10 
Rosiglitazone’s use was severely restricted in the United States 
soon after, in 2010, and was withdrawn from the market in 
the European Union (EU).11 
In response to this FDA crackdown, many companies have 
run two types of ads that are not required by law to include 
risk information: ‘reminder’ ads, which state the brand 
name, but make no health claims; or ‘disease-awareness’ ads, 
that name a condition but not the brand.12 When a viewer 
clicked into the latter, they were often redirected to a branded 
website (eg, clicking on http://www.managingra.info, on 
rheumatoid arthritis, one landed on http://www.orencia.com, 
a rheumatoid arthritis drug). Google announced in 2015 that 
it would no longer allow this redirection,13 closing a loophole 
that had allowed companies to skirt FDA regulations. 
Information Imbalance the Norm, not the Exception 
The violations that result in a regulatory letter likely represent 
a “tip of the iceberg” of inaccurate and misleading information 
in online DTCA. The Internet and social media represent 
enormous challenges to a limited team of reviewers, with 
ever-increasing volumes of materials, potentially hundreds 
of pages per website, and the ability for content to shift 
continuously.14 Although the FDA does not pre-screen online 
DTCA, manufacturers must submit promotional materials 
when they are first disseminated. However, the FDA can 
only review a small proportion of these materials because 
of limited staffing. DTCA volume has increased continually, 
reaching ~20 000 items in 2007.15 Even when the FDA does 
take regulatory action, many people may have been exposed 
to misleading messages before they are removed. In 2006, the 
US General Accounting Office found that the time from first 
public exposure to removal was on average eight months.15 
The Food and Drug Administration Amendments Act of 
2007 required that manufacturers submit certain television 
advertisements for pre-dissemination review by the FDA, but 
this provision does not extend to online promotion.16 
Egilman and Druar carried out a review of fraudulent 
pharmaceutical marketing in social media, extending beyond 
the examples highlighted in FDA letters.7 One issue addressed 
is YouTube and Twitter postings and websites in which the 
commercial sponsor is not listed. For example, Egilman 
and Druar cite the website for patients with type 2 diabetes, 
http://www.r3i.org, the ‘Residual Risk Reduction Initiative.’ 
This website was set up by Abbott in 2011 to promote their 
fenofibrate drug TriLipix for type 2 diabetes patients.7 In 
December 2015, the website and r3 initiative’s funding sources 
remain unstated. 
Whether benefit and risk information is equally prominent, 
as is required by US ‘fair balance’ provisions, depends strongly 
on placement within a website. Huh and Cude examined 
60 websites of commonly-prescribed brand-name drugs.17 
Around one third only mentioned benefits on their home 
page, and risks, when present, were often in smaller font. In 
2005, Sheehan carried out a similar study on 91 websites of 
top brands: 40% had no risk information on the home page, 
another 24% minimal risk information, and 76% of the time, 
the viewer had to scroll to reach risk information, if present.18 
These imbalances are important because of how often people 
search for medicines information online. In a 2008 survey, 
45% of Internet users had searched online for information 
on medicines.19 Two-thirds of search engine results for nearly 
300 commonly prescribed brands listed industry-sponsored 
sites as first ‘hits’ in three of four popular search engines.20 
The exception was Google USA, which has partnered with 
the National Institutes of Health (NIH) to give prominence to 
drug information from the NIH.21
Conclusion
FDA regulatory letters provide an important information 
source on the content of online advertising judged to violate 
US law. Kim recommends more explicit and comprehensive 
FDA guidelines for online DTCA.4 This step would be helpful 
but is unlikely to be sufficient to stop online DTCA from 
misleading the public. Regulatory violations for broadcast 
and print DTCA are frequent despite explicit FDA guidance 
concerning presentation of risk information.22 Given the 
strong pharmaceutical presence on high-volume social media 
sites and the global reach of social media, health and cost 
effects may well be felt globally.5 Widespread minimization 
of risk information in promotional websites is more likely to 
reflect the aim to sell a product than space constraints or lack 
of familiarity with US regulatory requirements. 
DTCA has become a prominent part of both the mass and 
online media landscape for nearly 20 years, and has been 
shown to influence patient demand and prescribing decisions, 
to be associated with shifts to less appropriate prescribing and 
less cost-effective treatments, and to maintain sales despite 
a price increase.1 Online DTCA is an integral part of these 
campaigns. 
The AMA’s call for a ban on DTCA in 2015 follows a 2007 
US Institute of Medicine call for a moratorium on DTCA in 
the first two years post approval as a safety measure, as new 
evidence of serious harm often emerges within this period.23 
These calls are an important step in opening up a discussion 
about whether public health and sustainability of healthcare 
services should be prioritized over commercial free speech. 
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Whether they translate to a shift in policy is likely to depend 
largely on political will. 
In 1990, Lou Morris, Acting Director of the FDA division 
regulating drug advertising, and David Banks wrote a 
commentary on five advertising “end-runs” at odds with 
US regulation.24 Two of these are highly relevant to online 
DTCA: the “publicity end-run” featuring various public 
relations activities, including celebrity endorsements, and the 
“consumer end-run,” then novel, skirting both the FDA and 
professionals to promote products directly to the public. They 
comment: “We are reminded of the old adage, ‘Cheer up, 
things could get worse.’ We cheered up and sure enough, things 
got worse.” With the sheer volume of ever-changing materials 
on the Internet, the large international reach of US online 
promotion, and the ease with which promotional websites 
and social media posts may obscure their sponsorship, this 
quip is more than apt today.
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